Df Dent & Co Holding in Fastenal Co (FAST) Has Cut as Valuation Rose; Chemocentryx (CCXI) Shares Rose While Bvf Cut Holding by $67.90 Million

Fastenal Company (NASDAQ:FAST) Logo

Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 78.1% based on its latest 2019Q1 regulatory filing with the SEC. Bvf Inc sold 5.22 million shares as the company’s stock rose 15.42% with the market. The hedge fund held 1.46 million shares of the health care company at the end of 2019Q1, valued at $20.34 million, down from 6.69 million at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $473.67 million market cap company. The stock decreased 1.45% or $0.12 during the last trading session, reaching $8.16. About 238,941 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 20, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 09/03/2018 ChemoCentryx 4Q EPS 80c; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M

Df Dent & Co Inc decreased its stake in Fastenal Co (FAST) by 8% based on its latest 2019Q1 regulatory filing with the SEC. Df Dent & Co Inc sold 192,537 shares as the company’s stock rose 2.08% with the market. The institutional investor held 2.22M shares of the building materials company at the end of 2019Q1, valued at $142.46 million, down from 2.41 million at the end of the previous reported quarter. Df Dent & Co Inc who had been investing in Fastenal Co for a number of months, seems to be less bullish one the $17.42B market cap company. The stock increased 0.23% or $0.07 during the last trading session, reaching $30.37. About 2.75 million shares traded. Fastenal Company (NASDAQ:FAST) has risen 24.22% since July 20, 2018 and is uptrending. It has outperformed by 19.79% the S&P500. Some Historical FAST News: 09/05/2018 – Fastenal Presenting at Macquarie Group Conference Tomorrow; 11/04/2018 – Fastenal Company to Host Investor Presentation; 11/04/2018 – Fastenal 1Q Operating Cash Flow $159.7M; 09/04/2018 – Fastenal Co expected to post earnings of 61 cents a share – Earnings Preview; 06/03/2018 – FASTENAL FEB. NET SALES UP 14.8%; 23/03/2018 – Fastenal Closes Below 50-Day Moving Average: Technicals; 01/05/2018 – Fastenal Company Recommends Rejection of Below-Market-Price Mini-Tender Offer by TRC Capital Corporation; 11/04/2018 – Fastenal 1Q-End Accounts Receivable Up 19.8%; 06/03/2018 FASTENAL FEB. DAILY SALES UP 14.8%; 11/04/2018 – Fastenal Sees 2018 Net Capital Expenditures About $149M

Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It improved, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Alps Advsr accumulated 0.01% or 122,039 shares. National Bank Of America Corp De holds 0% or 92,817 shares in its portfolio. Parametric Limited Company holds 55,490 shares or 0% of its portfolio. Raymond James has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). California State Teachers Retirement invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Prudential Fincl reported 22,040 shares stake. Carmignac Gestion owns 0.32% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.97M shares. Art Ltd Liability Corp has 0.02% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Ameriprise Fin Inc holds 261,396 shares or 0% of its portfolio. Geode Capital Ltd Liability Co has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Walleye Trading Llc accumulated 14,800 shares or 0% of the stock. One Trading LP invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Ny State Common Retirement Fund holds 0% or 25,400 shares in its portfolio. Pub Employees Retirement Systems Of Ohio holds 99,284 shares. The New York-based Blackrock has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

Bvf Inc, which manages about $999.89M and $893.07M US Long portfolio, upped its stake in Alpine Immune Sciences Inc by 558,658 shares to 1.20 million shares, valued at $8.24M in 2019Q1, according to the filing. It also increased its holding in Corvus Pharmaceuticals Inc by 218,835 shares in the quarter, for a total of 2.11M shares, and has risen its stake in Five Prime Therapeutics Inc (NASDAQ:FPRX).

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% – Tale of the Tape – NASDAQ” on October 17, 2014, also Globenewswire.com with their article: “ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer – GlobeNewswire” published on January 08, 2018, Seekingalpha.com published: “SCYNEXIS and ReWalk Robotics among healthcare gainers; Stellar Biotechnologies and ChemoCentryx among losers – Seeking Alpha” on June 05, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Finance.Yahoo.com and their article: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” published on May 09, 2019 as well as Seekingalpha.com‘s news article titled: “InflaRx Tanks 91.79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor ChemoCentryx – Seeking Alpha” with publication date: June 08, 2019.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 8. They expect $-0.21 EPS, down 50.00% or $0.07 from last year’s $-0.14 per share. After $-0.23 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -8.70% EPS growth.

Since January 22, 2019, it had 0 insider purchases, and 1 sale for $457,747 activity.

Since January 29, 2019, it had 0 insider purchases, and 4 sales for $3.57 million activity. The insider DOLAN MICHAEL JOHN sold $150,000. Another trade for 5,000 shares valued at $302,550 was sold by LUNDQUIST NICHOLAS J. Hein LeLand J also sold $2.49 million worth of Fastenal Company (NASDAQ:FAST) shares.

Investors sentiment decreased to 0.88 in Q1 2019. Its down 0.15, from 1.03 in 2018Q4. It turned negative, as 38 investors sold FAST shares while 229 reduced holdings. 76 funds opened positions while 159 raised stakes. 234.08 million shares or 1.90% less from 238.60 million shares in 2018Q4 were reported. Court Place Advsrs Lc accumulated 12,145 shares or 0.32% of the stock. Meeder Asset Mngmt holds 0.01% or 1,274 shares in its portfolio. Hightower Advisors Ltd Liability Corporation holds 0.04% or 90,679 shares. Hbk Sorce Advisory Ltd Limited Liability Company holds 0.02% or 3,684 shares in its portfolio. Trust Of Virginia Va has invested 0.98% in Fastenal Company (NASDAQ:FAST). Kornitzer Cap Ks stated it has 0.01% in Fastenal Company (NASDAQ:FAST). Essex Investment Co Llc stated it has 7,500 shares. Moreover, Parkside Fin Savings Bank & Tru has 0.06% invested in Fastenal Company (NASDAQ:FAST). Robeco Institutional Asset Bv invested in 0.07% or 313,553 shares. Greenleaf Trust reported 25,482 shares. 994,109 are owned by Amundi Pioneer Asset Management. Nuwave Mgmt Ltd Llc invested 0.03% of its portfolio in Fastenal Company (NASDAQ:FAST). Morgan Stanley holds 0.02% of its portfolio in Fastenal Company (NASDAQ:FAST) for 1.12M shares. Reilly Fin Advsrs Lc reported 759 shares stake. Harvey Inv Co Ltd Liability Co holds 3.95% of its portfolio in Fastenal Company (NASDAQ:FAST) for 357,482 shares.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

XBiotech Inc. (XBIT) EPS Estimated At $-0.15; Aar (AIR) Sentiment Is 1.55

AAR Corp. (NYSE:AIR) Logo

Aar Corp (AIR) investors sentiment increased to 1.55 in 2019 Q1. It’s up 0.47, from 1.08 in 2018Q4. The ratio has improved, as 93 hedge funds increased and started new equity positions, while 60 decreased and sold their stakes in Aar Corp. The hedge funds in our database now have: 30.23 million shares, down from 31.50 million shares in 2018Q4. Also, the number of hedge funds holding Aar Corp in top ten equity positions was flat from 1 to 1 for the same number . Sold All: 16 Reduced: 44 Increased: 54 New Position: 39.

Analysts expect XBiotech Inc. (NASDAQ:XBIT) to report $-0.15 EPS on August, 8.After having $-0.16 EPS previously, XBiotech Inc.’s analysts see -6.25% EPS growth. The stock decreased 0.70% or $0.05 during the last trading session, reaching $7.14. About 69,268 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 114.12% since July 20, 2018 and is uptrending. It has outperformed by 109.69% the S&P500. Some Historical XBIT News: 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG

Beach Point Capital Management Lp holds 4.53% of its portfolio in AAR Corp. for 562,826 shares. Tygh Capital Management Inc. owns 154,661 shares or 0.88% of their US portfolio. Moreover, Telemark Asset Management Llc has 0.82% invested in the company for 200,000 shares. The Wisconsin-based Heartland Advisors Inc has invested 0.47% in the stock. Prescott Group Capital Management L.L.C., a Oklahoma-based fund reported 63,270 shares.

The stock increased 0.69% or $0.29 during the last trading session, reaching $42.16. About 271,683 shares traded. AAR Corp. (AIR) has declined 29.46% since July 20, 2018 and is downtrending. It has underperformed by 33.89% the S&P500. Some Historical AIR News: 21/05/2018 – AAR CORP. UPDATES 4Q VIEW ON SLOWER RAMP-UP OF WASS PROGRAM; 20/03/2018 – AAR CORP AIR.N FY2019 SHR VIEW $2.73, REV VIEW $2.20 BLN — THOMSON REUTERS l/B/E/S; 21/05/2018 – AAR CORP – REAFFIRMING FISCAL 2019 GUIDANCE OF SALES IN THE RANGE OF $2.1 BILLION TO $2.2 BILLION; 24/05/2018 – CORRECT: AAR DID NOT REPORT 4Q RESULTS; 15/05/2018 – MARCATO REDUCED DXC, AIR IN 1Q: 13F; 20/03/2018 AAR Corp 3Q EPS 44c; 21/05/2018 – AAR SEES 4Q CONT OPS RESULTS SIMILAR, SLIGHTLY IMPROVED VS 3Q; 21/04/2018 – DJ AAR CORP, Inst Holders, 1Q 2018 (AIR); 20/03/2018 – AAR 3Q ADJ EPS CONT OPS 49C, EST. 50C; 20/03/2018 – AAR CORP – AFFIRMING GUIDANCE FOR FISCAL 2019

More notable recent AAR Corp. (NYSE:AIR) news were published by: Finance.Yahoo.com which released: “What Should Investors Know About AAR Corp.’s (NYSE:AIR) Growth? – Yahoo Finance” on July 12, 2019, also Finance.Yahoo.com with their article: “Why We’re Not Impressed By AAR Corp.’s (NYSE:AIR) 8.7% ROCE – Yahoo Finance” published on July 04, 2019, Seekingalpha.com published: “AAR Q4 2019 Earnings Preview – Seeking Alpha” on July 09, 2019. More interesting news about AAR Corp. (NYSE:AIR) were released by: Seekingalpha.com and their article: “AAR Corp.: Put This One On Your Watchlist – Seeking Alpha” published on July 15, 2019 as well as Seekingalpha.com‘s news article titled: “Delta Air Lines: Breaking Higher – Seeking Alpha” with publication date: July 16, 2019.

AAR CORP. provides products and services to commercial aviation, government, and defense markets worldwide. The company has market cap of $1.48 billion. The companyÂ’s Aviation Services segment offers aftermarket support and services; inventory management and distribution services; and maintenance, repair, and overhaul, as well as engineering services. It has a 205.66 P/E ratio. This segment also sells and leases new, overhauled, and repaired engine and airframe parts and components; and provides inventory and repair programs, warranty claim management, and outsourcing programs for engine and airframe parts and components, as well as performance logistics programs in support of the U.S.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Finance.Yahoo.com which released: “What Kind Of Investor Owns Most Of XBiotech Inc. (NASDAQ:XBIT)? – Yahoo Finance” on July 16, 2019, also Nasdaq.com with their article: “Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis – Nasdaq” published on July 11, 2019, Nasdaq.com published: “XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board – Nasdaq” on July 10, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Nasdaq.com and their article: “Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients – Nasdaq” published on July 09, 2019 as well as Globenewswire.com‘s news article titled: “XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa – GlobeNewswire” with publication date: June 25, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $292.47 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

AAR Corp. (NYSE:AIR) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

EPS for ChemoCentryx, Inc. (CCXI) Expected At $-0.21; Ubs Oconnor Trimmed Its Equity L (ELS) Position

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.21 EPS on August, 8.They anticipate $0.07 EPS change or 50.00% from last quarter’s $-0.14 EPS. After having $-0.23 EPS previously, ChemoCentryx, Inc.’s analysts see -8.70% EPS growth. The stock decreased 1.45% or $0.12 during the last trading session, reaching $8.16. About 238,941 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 20, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Ubs Oconnor Llc decreased Equity L (ELS) stake by 36.19% reported in 2019Q1 SEC filing. Ubs Oconnor Llc sold 15,600 shares as Equity L (ELS)’s stock rose 8.88%. The Ubs Oconnor Llc holds 27,500 shares with $3.14 billion value, down from 43,100 last quarter. Equity L now has $11.05 billion valuation. The stock decreased 2.09% or $2.62 during the last trading session, reaching $122.79. About 386,522 shares traded. Equity LifeStyle Properties, Inc. (NYSE:ELS) has risen 32.18% since July 20, 2018 and is uptrending. It has outperformed by 27.75% the S&P500.

Investors sentiment increased to 1.28 in 2019 Q1. Its up 0.02, from 1.26 in 2018Q4. It increased, as 16 investors sold ELS shares while 85 reduced holdings. 41 funds opened positions while 88 raised stakes. 80.77 million shares or 0.50% less from 81.17 million shares in 2018Q4 were reported. Natixis Advsr Lp invested 0.04% in Equity LifeStyle Properties, Inc. (NYSE:ELS). Nuveen Asset Mngmt invested 0.21% in Equity LifeStyle Properties, Inc. (NYSE:ELS). Alliancebernstein L P, New York-based fund reported 90,179 shares. Stifel Financial holds 0.01% of its portfolio in Equity LifeStyle Properties, Inc. (NYSE:ELS) for 21,615 shares. Moreover, Schroder Inv Gru has 0.2% invested in Equity LifeStyle Properties, Inc. (NYSE:ELS). First Republic Investment Management, a California-based fund reported 22,913 shares. United Kingdom-based Lmr Prns Llp has invested 0.2% in Equity LifeStyle Properties, Inc. (NYSE:ELS). M&T Bankshares stated it has 0.01% in Equity LifeStyle Properties, Inc. (NYSE:ELS). Dekabank Deutsche Girozentrale reported 11,192 shares. Duncker Streett And reported 66 shares stake. Strategic Global invested 0.3% in Equity LifeStyle Properties, Inc. (NYSE:ELS). Presima holds 1.99% or 126,700 shares in its portfolio. Asset One Communication Ltd invested in 197,987 shares. Sumitomo Mitsui Tru Holdings reported 57,375 shares. Raymond James And Associate invested in 0% or 2,619 shares.

Analysts await Equity LifeStyle Properties, Inc. (NYSE:ELS) to report earnings on July, 22. They expect $0.94 earnings per share, up 4.44% or $0.04 from last year’s $0.9 per share. ELS’s profit will be $84.60 million for 32.66 P/E if the $0.94 EPS becomes a reality. After $1.13 actual earnings per share reported by Equity LifeStyle Properties, Inc. for the previous quarter, Wall Street now forecasts -16.81% negative EPS growth.

Ubs Oconnor Llc increased Dish Net (Prn) stake by 40.00M shares to 41.00M valued at $33.82 billion in 2019Q1. It also upped Sba Comm stake by 12,300 shares and now owns 26,700 shares. T Mobile (NYSE:TMUS) was raised too.

Since February 4, 2019, it had 0 buys, and 1 sale for $694,524 activity. 6,581 shares valued at $694,524 were sold by CONTIS DAVID J on Monday, February 4.

More notable recent Equity LifeStyle Properties, Inc. (NYSE:ELS) news were published by: Finance.Yahoo.com which released: “Is Equity LifeStyle Properties, Inc. (NYSE:ELS) An Attractive Dividend Stock? – Yahoo Finance” on July 08, 2019, also Finance.Yahoo.com with their article: “Is Equity Lifestyle Properties, Inc. (ELS) A Good Stock To Buy? – Yahoo Finance” published on June 24, 2019, Investorplace.com published: “7 A-Rated Stocks to Buy for the Rest of 2019 – Investorplace.com” on July 07, 2019. More interesting news about Equity LifeStyle Properties, Inc. (NYSE:ELS) were released by: Finance.Yahoo.com and their article: “Here’s What Hedge Funds Think About Federal Realty Investment Trust (FRT) – Yahoo Finance” published on July 05, 2019 as well as Prnewswire.com‘s news article titled: “79 Encore RV Resorts and Thousand Trails Campgrounds Earn TripAdvisor’s 2019 Certificate of Excellence – PRNewswire” with publication date: July 02, 2019.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Finance.Yahoo.com which released: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” on May 09, 2019, also Seekingalpha.com with their article: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” published on June 05, 2019, Globenewswire.com published: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” on May 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” published on March 28, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” with publication date: September 28, 2018.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $473.67 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Since January 22, 2019, it had 0 insider purchases, and 1 insider sale for $457,747 activity. KANAYA SUSAN M sold 37,893 shares worth $457,747.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 6 analyst reports since February 11, 2019 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 12. On Wednesday, March 27 the stock rating was upgraded by FBR Capital to “Buy”. Leerink Swann initiated the stock with “Buy” rating in Thursday, February 14 report.

Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It improved, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Vanguard Gru Inc invested in 1.29 million shares or 0% of the stock. Bb&T Secs Ltd holds 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 134,827 shares. Goldman Sachs Group Incorporated holds 0% or 193,160 shares. Moreover, Secor Cap Advisors Ltd Partnership has 0.04% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 12,798 shares. Credit Suisse Ag holds 13,053 shares or 0% of its portfolio. Sectoral Asset invested in 0.03% or 17,811 shares. Federated Incorporated Pa has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Alps reported 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Charles Schwab Mngmt holds 49,177 shares or 0% of its portfolio. Farallon Mgmt Limited Com accumulated 1.50M shares. Consonance Capital Management Ltd Partnership owns 1.67 million shares for 1.46% of their portfolio. Daiwa Securities has 269 shares for 0% of their portfolio. Employees Retirement System Of Ohio invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Raymond James And holds 0% or 13,874 shares. Dekabank Deutsche Girozentrale reported 20,000 shares or 0% of all its holdings.

Equity LifeStyle Properties, Inc. (NYSE:ELS) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

Principal Financial Group (PFG) Holder Old Republic International Has Trimmed Stake; Bvf Holding in Chemocentryx (CCXI) Lowered by $67.90 Million as Share Value Rose

Principal Financial Group, Inc. (NASDAQ:PFG) Logo

Old Republic International Corp decreased its stake in Principal Financial Group (PFG) by 17.03% based on its latest 2019Q1 regulatory filing with the SEC. Old Republic International Corp sold 102,000 shares as the company’s stock rose 11.32% with the market. The institutional investor held 497,000 shares of the accident &health insurance company at the end of 2019Q1, valued at $24.94M, down from 599,000 at the end of the previous reported quarter. Old Republic International Corp who had been investing in Principal Financial Group for a number of months, seems to be less bullish one the $16.64B market cap company. The stock increased 0.05% or $0.03 during the last trading session, reaching $59.73. About 168,137 shares traded. Principal Financial Group, Inc. (NYSE:PFG) has declined 7.33% since July 19, 2018 and is downtrending. It has underperformed by 11.76% the S&P500. Some Historical PFG News: 19/03/2018 – TETRAPHASE PHARMACEUTICALS – BOARD ELECTED CHRISTOPHER WATT AS PRINCIPAL FINANCIAL OFFICER & PRINCIPAL ACCOUNTING OFFICER UNTIL CFO IS NAMED; 26/04/2018 – PRINCIPAL BOOSTS QTR DIV TO 52C/SHR FROM 51C, EST. 51C; 14/05/2018 – Principal Financial Group Inc. Exits Position in Ares Capital; 16/04/2018 – PFG REPORTS PRINCIPAL INTL OTHER ENTITIES AUM $173.8B MARCH 31; 26/04/2018 – B. RILEY FINANCIAL – BEBE’S BOARD ACCEPTED RESIGNATION OF JOE SCIROCCO, ITS PRINCIPAL FINANCIAL & ACCOUNTING OFFICER, EFFECTIVE AS OF APRIL 20; 14/05/2018 – Principal Financial Group Inc. Exits Position in Validus; 02/05/2018 – Principal Names New Chief Human Resources Officer; 22/03/2018 – FLOTEK INDUSTRIES – MATTHEW MARIETTA PROMOTED TO EXECUTIVE VICE PRESIDENT OF FINANCE & CORPORATE DEVELOPMENT, TO SERVE AS PRINCIPAL FINANCIAL OFFICER; 22/05/2018 – ADVISORY-Ignore research alert on Principal Financial Group Inc; 30/03/2018 – BRIEF-Moody’s Corp Says Designated Michael Crimmins To Serve On Interim Basis As Co’s Principal Financial Officer

Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 78.1% based on its latest 2019Q1 regulatory filing with the SEC. Bvf Inc sold 5.22 million shares as the company’s stock rose 15.42% with the market. The hedge fund held 1.46M shares of the health care company at the end of 2019Q1, valued at $20.34 million, down from 6.69M at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $471.64 million market cap company. The stock decreased 1.87% or $0.15 during the last trading session, reaching $8.12. About 14,082 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 19, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9

Old Republic International Corp, which manages about $3.71 billion US Long portfolio, upped its stake in Cardinal Health Inc (NYSE:CAH) by 379,000 shares to 1.02M shares, valued at $49.31M in 2019Q1, according to the filing. It also increased its holding in South Jersey Industries Inc (NYSE:SJI) by 472,000 shares in the quarter, for a total of 1.19 million shares, and has risen its stake in Dominion Resources Inc (NYSE:D).

Analysts await Principal Financial Group, Inc. (NASDAQ:PFG) to report earnings on July, 25. They expect $1.38 EPS, up 2.22% or $0.03 from last year’s $1.35 per share. PFG’s profit will be $384.40M for 10.82 P/E if the $1.38 EPS becomes a reality. After $1.43 actual EPS reported by Principal Financial Group, Inc. for the previous quarter, Wall Street now forecasts -3.50% negative EPS growth.

Since February 1, 2019, it had 0 insider buys, and 1 insider sale for $50,170 activity.

Investors sentiment increased to 0.98 in Q1 2019. Its up 0.02, from 0.96 in 2018Q4. It improved, as 29 investors sold PFG shares while 160 reduced holdings. 63 funds opened positions while 123 raised stakes. 194.29 million shares or 1.52% less from 197.29 million shares in 2018Q4 were reported. 649,000 were reported by Ny State Common Retirement Fund. 91,674 are held by Principal Group Inc. 7,353 were reported by Wetherby Asset Mngmt Inc. 74,834 are owned by Hightower Advsrs Limited Liability Corp. Tealwood Asset Management stated it has 53,007 shares or 1.13% of all its holdings. Texas Permanent School Fund holds 0.04% or 50,355 shares. 1,250 were reported by Vigilant Cap Mngmt Lc. Allstate holds 47,518 shares. Asset Mngmt Incorporated holds 0.35% or 9,297 shares in its portfolio. 10,095 are owned by Northwestern Mutual Wealth Management. Optimum Inv Advisors reported 1,819 shares. Eaton Vance Mngmt holds 81,437 shares. Acadian Asset Management Limited Liability Corporation reported 162,538 shares or 0.04% of all its holdings. Gp One Trading Lp reported 173 shares. Mutual Of Omaha Bank & Trust Wealth Management reported 7,326 shares or 0.11% of all its holdings.

More notable recent Principal Financial Group, Inc. (NASDAQ:PFG) news were published by: Nasdaq.com which released: “Zacks.com featured highlights include: Hibbett Sports, Comtech, Quanta Services, Principal Financial and Zions – Nasdaq” on June 24, 2019, also Finance.Yahoo.com with their article: “Here’s What We Think About Principal Financial Group, Inc.’s (NASDAQ:PFG) CEO Pay – Yahoo Finance” published on May 14, 2019, Businesswire.com published: “Principal to Announce Second Quarter 2019 Financial Results – Business Wire” on July 02, 2019. More interesting news about Principal Financial Group, Inc. (NASDAQ:PFG) were released by: Seekingalpha.com and their article: “Principal Financial Group: Nothing Wrong With Growing Inorganically – Seeking Alpha” published on April 15, 2019 as well as Nasdaq.com‘s news article titled: “New Strong Buy Stocks for July 16th – Nasdaq” with publication date: July 16, 2019.

Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. The Georgia-based Voya Inv Mgmt Ltd Liability Corporation has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ameritas Inv Prns invested in 0% or 2,120 shares. Acadian Asset Management Limited Liability Corp reported 0.05% stake. Wells Fargo And Com Mn owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 127,125 shares. Employees Retirement Systems Of Texas invested 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Fincl Bank Of New York Mellon owns 133,619 shares or 0% of their US portfolio. Citigroup stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Panagora Asset invested in 308,857 shares. Arrowstreet Partnership has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Tiaa Cref Inv Management Ltd Company accumulated 288,597 shares. Dekabank Deutsche Girozentrale accumulated 20,000 shares. 207,029 are owned by Baker Bros Advsrs Limited Partnership. 122,039 were reported by Alps Advsrs Inc. Daiwa Securities invested in 0% or 269 shares. Fernwood Inv Mgmt Ltd Liability Co owns 10,000 shares.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 8. They expect $-0.21 earnings per share, down 50.00% or $0.07 from last year’s $-0.14 per share. After $-0.23 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -8.70% EPS growth.

Bvf Inc, which manages about $999.89M and $893.07M US Long portfolio, upped its stake in Merus N V by 25,000 shares to 4.54 million shares, valued at $67.06M in 2019Q1, according to the filing. It also increased its holding in Replimune Group Inc by 707,200 shares in the quarter, for a total of 1.61 million shares, and has risen its stake in Molecular Templates Inc.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “InflaRx Update: Pipeline Continues To Progress, Data In 1H 2019 – Seeking Alpha” on November 24, 2018, also Fool.com with their article: “Better Know Biotech: 2 Stocks You Ought to Know About – Motley Fool” published on May 16, 2018, Globenewswire.com published: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” on March 28, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” published on May 06, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference – GlobeNewswire” with publication date: September 26, 2018.

Principal Financial Group, Inc. (NASDAQ:PFG) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

InflaRx N.V. (IFRX) Reaches $2.89 52-Week Low; Aqr Capital Management Raised Lancaster Colony (LANC) Holding By $5.97 Million

The stock of InflaRx N.V. (NASDAQ:IFRX) hit a new 52-week low and has $2.63 target or 9.00% below today’s $2.89 share price. The 8 months bearish chart indicates high risk for the $75.00 million company. The 1-year low was reported on Jul, 19 by Barchart.com. If the $2.63 price target is reached, the company will be worth $6.75M less. The stock decreased 8.01% or $0.2514 during the last trading session, reaching $2.8886. About 3.37M shares traded or 98.55% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since July 19, 2018 and is uptrending. It has outperformed by 16.11% the S&P500. Some Historical IFRX News: 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs

Aqr Capital Management Llc increased Lancaster Colony Corp (LANC) stake by 24.29% reported in 2019Q1 SEC filing. Aqr Capital Management Llc acquired 38,281 shares as Lancaster Colony Corp (LANC)’s stock declined 5.64%. The Aqr Capital Management Llc holds 195,893 shares with $30.63M value, up from 157,612 last quarter. Lancaster Colony Corp now has $4.13B valuation. The stock decreased 0.44% or $0.66 during the last trading session, reaching $150.14. About 25,652 shares traded. Lancaster Colony Corporation (NASDAQ:LANC) has risen 18.13% since July 19, 2018 and is uptrending. It has outperformed by 13.70% the S&P500. Some Historical LANC News: 14/03/2018 – Lancaster Colony at Group Meeting Hosted By CL King Today; 26/04/2018 – LANCASTER COLONY CORP – HAVE INITIATIVES IN PLACE OR PLANNED FOR BOTH SHORT- AND LONG-TERM TO ADDRESS HIGHER FREIGHT AND COMMODITY COSTS; 26/04/2018 – Lancaster Colony 3Q EPS $1.00; 24/04/2018 – Lancaster Colony Short-Interest Ratio Rises 84% to 9 Days; 24/04/2018 – Lancaster Colony Volume Jumps More Than Five Times Average; 29/03/2018 – Lancaster Colony Closes Above 50-Day Moving Average: Technicals; 26/04/2018 – LANCASTER COLONY 3Q EPS $1.00, EST. $1.06; 26/04/2018 – LANCASTER COLONY CORP – POSITIONED TO RETURN TO GROWTH AND RESUME PROMOTIONAL SUPPORT FOR FROZEN GARLIC BREAD PRODUCT LINE IN COMING QUARTERS; 21/04/2018 – DJ Lancaster Colony Corporation, Inst Holders, 1Q 2018 (LANC); 20/04/2018 – Lancaster Colony Closes Below 200-Day Moving Average

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $75.00 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Seekingalpha.com which released: “InflaRx up 6% after hours on additional IFX-1 data – Seeking Alpha” on July 18, 2019, also Finance.Yahoo.com with their article: “Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) – Yahoo Finance” published on June 29, 2019, Nasdaq.com published: “Health Care Sector Update for 07/19/2019: MTP, ATRA, IFRX, JNJ, ABT, MRK, PFE, AMGN – Nasdaq” on July 19, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Benzinga.com and their article: “26 Stocks Moving In Friday’s Pre-Market Session – Benzinga” published on July 19, 2019 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 07/19: (CRWD) (JCP) (MIK) Higher; (MVIS) (RRGB) (SKX) (more…) – StreetInsider.com” with publication date: July 19, 2019.

Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on August, 8. They expect $-0.55 earnings per share, down 358.33% or $0.43 from last year’s $-0.12 per share. After $-0.43 actual earnings per share reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 27.91% negative EPS growth.

More notable recent Lancaster Colony Corporation (NASDAQ:LANC) news were published by: Finance.Yahoo.com which released: “Is Lancaster Colony Corporation (NASDAQ:LANC) As Strong As Its Balance Sheet Indicates? – Yahoo Finance” on July 02, 2019, also Finance.Yahoo.com with their article: “Hedge Funds Have Never Been This Bullish On Lancaster Colony Corporation (LANC) – Yahoo Finance” published on June 20, 2019, Finance.Yahoo.com published: “Here’s What Hedge Funds Think About Hospitality Properties Trust (HPT) – Yahoo Finance” on June 28, 2019. More interesting news about Lancaster Colony Corporation (NASDAQ:LANC) were released by: Nasdaq.com and their article: “RSI Alert: Lancaster Colony Now Oversold – Nasdaq” published on May 31, 2019 as well as Seekingalpha.com‘s news article titled: “Lancaster Is An Emerging Leader – Seeking Alpha” with publication date: February 07, 2019.

Investors sentiment increased to 2.27 in Q1 2019. Its up 0.97, from 1.3 in 2018Q4. It improved, as 10 investors sold LANC shares while 49 reduced holdings. 57 funds opened positions while 77 raised stakes. 14.94 million shares or 4.73% less from 15.68 million shares in 2018Q4 were reported. Commonwealth Of Pennsylvania Public School Empls Retrmt System reported 0.01% stake. Renaissance Ltd Com has invested 0.1% in Lancaster Colony Corporation (NASDAQ:LANC). Gsa Capital Prns Limited Liability Partnership holds 0.05% or 3,203 shares in its portfolio. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Mngmt reported 0.01% of its portfolio in Lancaster Colony Corporation (NASDAQ:LANC). Toronto Dominion Fincl Bank holds 0% of its portfolio in Lancaster Colony Corporation (NASDAQ:LANC) for 1 shares. Federated Investors Pa holds 0% or 6,271 shares. Captrust Fincl holds 162 shares. Segall Bryant & Hamill Ltd Liability Company owns 13,847 shares. Bnp Paribas Arbitrage has invested 0% of its portfolio in Lancaster Colony Corporation (NASDAQ:LANC). Fifth Third Bancorp owns 0.02% invested in Lancaster Colony Corporation (NASDAQ:LANC) for 21,916 shares. Principal Gp has 0.01% invested in Lancaster Colony Corporation (NASDAQ:LANC) for 87,376 shares. Ubs Asset Mngmt Americas Inc holds 15,384 shares or 0% of its portfolio. Stone Ridge Asset Mngmt Limited holds 0.05% of its portfolio in Lancaster Colony Corporation (NASDAQ:LANC) for 5,591 shares. Moreover, Johnson Invest Counsel has 0.03% invested in Lancaster Colony Corporation (NASDAQ:LANC). Sg Americas Securities Ltd Liability Co accumulated 0.01% or 8,210 shares.

Aqr Capital Management Llc decreased Cboe Global Markets Inc (NASDAQ:CBOE) stake by 126,843 shares to 70,492 valued at $6.70 million in 2019Q1. It also reduced Berkshire Hathaway Inc Del (BRKB) stake by 28,601 shares and now owns 2.42M shares. Manpowergroup Inc (NYSE:MAN) was reduced too.

Lancaster Colony Corporation (NASDAQ:LANC) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

United States Hidradenitis Suppurativa Market, 2014-2019 & 2024 – Pipeline, Epidemiology, Market Valuations, Drugs (Sales & Market Share), and Competitive Landscape – ResearchAndMarkets.com

DUBLIN–()–The “US Hidradenitis Suppurativa Market and Competitive Landscape – 2019” report has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights into Hidradenitis Suppurativa pipeline products, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa market valuations and forecast, Hidradenitis Suppurativa drugs sales and competitive landscape in the US.

The research is classified into seven sections – Hidradenitis Suppurativa treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.

Research Scope

  • Hidradenitis Suppurativa pipeline: Find out the products in clinical trials for the treatment of Hidradenitis Suppurativa by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
  • Hidradenitis Suppurativa epidemiology: Find out the number of patients diagnosed (prevalence) with Hidradenitis Suppurativa in the US
  • Hidradenitis Suppurativa drugs: Identify key products marketed and prescribed for Hidradenitis Suppurativa in the US, including trade name, molecule name, and company
  • Hidradenitis Suppurativa drugs sales: Find out the sales revenues of Hidradenitis Suppurativa drugs in the US
  • Hidradenitis Suppurativa market valuations: Find out the market size for Hidradenitis Suppurativa drugs in 2018 in the US. Find out how the market advanced from 2014 and forecast to 2024
  • Hidradenitis Suppurativa drugs market share: Find out the market shares for key Hidradenitis Suppurativa drugs in the US

Benefits of this Research

  • Support monitoring and reporting national Hidradenitis Suppurativa market analysis and sales trends
  • Track competitor drugs sales and market share in the US Hidradenitis Suppurativa market
  • Track competitive developments in Hidradenitis Suppurativa market and present key issues and learnings
  • Synthesize insights for Hidradenitis Suppurativa market and products to drive business performance
  • Answer key business questions about the Hidradenitis Suppurativa market
  • Evaluate commercial market opportunity assessment, positioning, and segmentation for Hidradenitis Suppurativa products
  • Supports decision making in R&D to long term marketing strategies

Key Topics Covered

1) Hidradenitis Suppurativa Treatments

2) Hidradenitis Suppurativa Pipeline

3) US Hidradenitis Suppurativa Epidemiology

4) Marketed Drugs for Hidradenitis Suppurativa in US

5) US Hidradenitis Suppurativa Market Size and Forecast

6) US Hidradenitis Suppurativa Products Sales and Forecast

7) US Hidradenitis Suppurativa Market Competitive Landscape

8) Methodology

List of Tables

1. Hidradenitis Suppurativa Phase 3 Clinical Trials, 2019

2. Hidradenitis Suppurativa Phase 2 Clinical Trials, 2019

3. Hidradenitis Suppurativa Phase 1 Clinical Trials, 2019

4. Hidradenitis Suppurativa Epidemiology, US, 2014 – 2024

5. Marketed Drugs for Hidradenitis Suppurativa, US, 2018

6. Hidradenitis Suppurativa Market Size and Forecast ($), US, 2014 – 2024

7. Hidradenitis Suppurativa Product Sales ($), US, 2014 – 2024

List of Figures

1. Hidradenitis Suppurativa Epidemiology, US, 2014 – 2024

2. Hidradenitis Suppurativa Market Size and Forecast ($), US, 2014 – 2024

3. Hidradenitis Suppurativa Products Market Share (%), US, 2018

For more information about this report visit https://www.researchandmarkets.com/r/zhwf0t

Source link

InflaRx N.V. (IFRX) Reaches $2.86 Low on Jul, 19; Credit Suisse Ag Decreased By $1.71 Million Its Weight Watchers Intl New (Call) (WTW) Stake

Credit Suisse Ag decreased Weight Watchers Intl Inc New (Call) (WTW) stake by 63.14% reported in 2019Q1 SEC filing. Credit Suisse Ag sold 85,650 shares as Weight Watchers Intl Inc New (Call) (WTW)’s stock 0.00%. The Credit Suisse Ag holds 50,000 shares with $1.01M value, down from 135,650 last quarter. Weight Watchers Intl Inc New (Call) now has $ valuation. It closed at $19.07 lastly. It is up 0.00% since July 19, 2018 and is . It has underperformed by 4.43% the S&P500. Some Historical WTW News: 10/05/2018 – WEIGHT WATCHERS REPORTS PRICING OF SECONDARY OFFERING BY ARTAL; 05/04/2018 – WEIGHT WATCHERS INTERNATIONAL SAYS CEO MINDY GROSSMAN’S FY 2017 TOTAL COMPENSATION WAS $33.4 MLN – SEC FILING; 08/05/2018 – Moody’s Cites Sale by Weight Watchers Controlling Shareholder; 08/05/2018 – Moody’s Upgrades Weight Watchers Corporate Family Rating to Ba3 From B1; 18/04/2018 – WEIGHT WATCHERS INTERNATIONAL INC WTW.N : CRAIG HALLUM SAYS FRESHREALM PARTNERSHIP REPRESENTS MEANINGFUL EXPANSION OF WEIGHT WATCHERS BRAND; 14/05/2018 – Weight Watchers Presenting at JPMorgan Conference May 17; 15/05/2018 – Melvin Capital Management Buys 1.1% Position in Weight Watchers; 05/04/2018 – Oprah-Backed Weight Watchers Awards CEO Grossman $33.4 Million; 10/05/2018 – WEIGHT WATCHERS OFFERING PRICES AT $69/SHR; 12/04/2018 – RealSelf Appoints First Chief Marketing Officer

The stock of InflaRx N.V. (NASDAQ:IFRX) reached all time low today, Jul, 19 and still has $2.72 target or 5.00% below today’s $2.86 share price. This indicates more downside for the $74.26M company. This technical setup was reported by Barchart.com. If the $2.72 PT is reached, the company will be worth $3.71M less. The stock decreased 8.92% or $0.28 during the last trading session, reaching $2.86. About 3.39M shares traded or 99.93% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since July 19, 2018 and is uptrending. It has outperformed by 16.11% the S&P500. Some Historical IFRX News: 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6

More notable recent Weight Watchers International, Inc. (NASDAQ:WTW) news were published by: Finance.Yahoo.com which released: “Is Weight Watchers International, Inc. (WTW) A Good Stock To Buy? – Yahoo Finance” on April 29, 2019, also Investorplace.com with their article: “Time to Nibble on Weight Watchers Stock – Investorplace.com” published on April 16, 2019, Benzinga.com published: “Morgan Stanley: The Street Is Overestimating Weight Watchers’ Addressable Market – Benzinga” on September 13, 2018. More interesting news about Weight Watchers International, Inc. (NASDAQ:WTW) were released by: Seekingalpha.com and their article: “Weight Watchers Q4 2018 Earnings Preview – Seeking Alpha” published on February 25, 2019 as well as Investorplace.com‘s news article titled: “Grossman Is Engineering a Real Weight Watchers Stock Turnaround – Investorplace.com” with publication date: September 12, 2018.

Investors sentiment decreased to 0.83 in Q1 2019. Its down 0.36, from 1.19 in 2018Q4. It dived, as 79 investors sold WTW shares while 41 reduced holdings. 38 funds opened positions while 62 raised stakes. 54.86 million shares or 3.39% less from 56.79 million shares in 2018Q4 were reported. Sg Americas Securities Limited Liability Company accumulated 10,109 shares. Oregon Employees Retirement Fund owns 15,357 shares. Globeflex Cap Ltd Partnership holds 0.06% of its portfolio in Weight Watchers International, Inc. (NASDAQ:WTW) for 15,101 shares. Jpmorgan Chase Communication owns 29,582 shares or 0% of their US portfolio. Employees Retirement Association Of Colorado has invested 0% in Weight Watchers International, Inc. (NASDAQ:WTW). Guggenheim Limited Liability has 17,240 shares for 0% of their portfolio. 15,507 are held by Auxier Asset Mgmt. New South Capital Mgmt reported 0.35% stake. Metropolitan Life Insurance Com New York reported 0.03% stake. 134 were accumulated by Ubs Asset Americas Inc. 26,649 were reported by Phoenix Inv Adviser Lc. Retail Bank Of Montreal Can holds 0% of its portfolio in Weight Watchers International, Inc. (NASDAQ:WTW) for 8,171 shares. 2,401 are owned by Zurcher Kantonalbank (Zurich Cantonalbank). Legal General Grp Inc Public Limited stated it has 0% of its portfolio in Weight Watchers International, Inc. (NASDAQ:WTW). Hsbc Holdings Plc reported 20,745 shares or 0% of all its holdings.

Credit Suisse Ag increased Alarm Com Hldgs Inc stake by 22,174 shares to 49,940 valued at $3.24M in 2019Q1. It also upped Ctrip Com Intl Ltd (Prn) stake by 870,000 shares and now owns 3.87 million shares. Ford Mtr Co Del (NYSE:F) was raised too.

Among 7 analysts covering Weight Watchers Intl (NYSE:WTW), 1 have Buy rating, 2 Sell and 4 Hold. Therefore 14% are positive. Weight Watchers Intl had 17 analyst reports since February 11, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, February 20 by Craig Hallum. The stock of Weight Watchers International, Inc. (NASDAQ:WTW) earned “Buy” rating by Sidoti on Wednesday, February 27. DA Davidson downgraded Weight Watchers International, Inc. (NASDAQ:WTW) on Wednesday, February 27 to “Neutral” rating. The stock has “Sell” rating by J.P. Morgan on Tuesday, February 19. The company was downgraded on Tuesday, February 19 by JP Morgan. The stock has “Hold” rating by Morgan Stanley on Friday, March 1. The stock of Weight Watchers International, Inc. (NASDAQ:WTW) earned “Neutral” rating by FBR Capital on Wednesday, February 27. As per Wednesday, February 27, the company rating was maintained by J.P. Morgan. The rating was maintained by UBS with “Hold” on Wednesday, February 27. The rating was maintained by Sidoti on Monday, February 11 with “Buy”.

Since March 1, 2019, it had 1 buying transaction, and 0 insider sales for $260,446 activity. On Friday, March 1 the insider GROSSMAN MINDY F bought $260,446.

Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on August, 8. They expect $-0.55 EPS, down 358.33% or $0.43 from last year’s $-0.12 per share. After $-0.43 actual EPS reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 27.91% negative EPS growth.

Weight Watchers International, Inc. (NASDAQ:WTW) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

United States Hidradenitis Suppurativa Market, 2014-2019 & 2024 – Pipeline, Epidemiology, Market Valuations, Drugs (Sales & Market Share), and Competitive Landscape

DUBLIN–(BUSINESS WIRE)–

The “US Hidradenitis Suppurativa Market and Competitive Landscape – 2019” report has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights into Hidradenitis Suppurativa pipeline products, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa market valuations and forecast, Hidradenitis Suppurativa drugs sales and competitive landscape in the US.

The research is classified into seven sections – Hidradenitis Suppurativa treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.

Research Scope

  • Hidradenitis Suppurativa pipeline: Find out the products in clinical trials for the treatment of Hidradenitis Suppurativa by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
  • Hidradenitis Suppurativa epidemiology: Find out the number of patients diagnosed (prevalence) with Hidradenitis Suppurativa in the US
  • Hidradenitis Suppurativa drugs: Identify key products marketed and prescribed for Hidradenitis Suppurativa in the US, including trade name, molecule name, and company
  • Hidradenitis Suppurativa drugs sales: Find out the sales revenues of Hidradenitis Suppurativa drugs in the US
  • Hidradenitis Suppurativa market valuations: Find out the market size for Hidradenitis Suppurativa drugs in 2018 in the US. Find out how the market advanced from 2014 and forecast to 2024
  • Hidradenitis Suppurativa drugs market share: Find out the market shares for key Hidradenitis Suppurativa drugs in the US

Benefits of this Research

  • Support monitoring and reporting national Hidradenitis Suppurativa market analysis and sales trends
  • Track competitor drugs sales and market share in the US Hidradenitis Suppurativa market
  • Track competitive developments in Hidradenitis Suppurativa market and present key issues and learnings
  • Synthesize insights for Hidradenitis Suppurativa market and products to drive business performance
  • Answer key business questions about the Hidradenitis Suppurativa market
  • Evaluate commercial market opportunity assessment, positioning, and segmentation for Hidradenitis Suppurativa products
  • Supports decision making in R&D to long term marketing strategies

Key Topics Covered

1) Hidradenitis Suppurativa Treatments

2) Hidradenitis Suppurativa Pipeline

3) US Hidradenitis Suppurativa Epidemiology

4) Marketed Drugs for Hidradenitis Suppurativa in US

5) US Hidradenitis Suppurativa Market Size and Forecast

6) US Hidradenitis Suppurativa Products Sales and Forecast

7) US Hidradenitis Suppurativa Market Competitive Landscape

8) Methodology

List of Tables

1. Hidradenitis Suppurativa Phase 3 Clinical Trials, 2019

2. Hidradenitis Suppurativa Phase 2 Clinical Trials, 2019

3. Hidradenitis Suppurativa Phase 1 Clinical Trials, 2019

4. Hidradenitis Suppurativa Epidemiology, US, 2014 – 2024

5. Marketed Drugs for Hidradenitis Suppurativa, US, 2018

6. Hidradenitis Suppurativa Market Size and Forecast ($), US, 2014 – 2024

7. Hidradenitis Suppurativa Product Sales ($), US, 2014 – 2024

List of Figures

1. Hidradenitis Suppurativa Epidemiology, US, 2014 – 2024

2. Hidradenitis Suppurativa Market Size and Forecast ($), US, 2014 – 2024

3. Hidradenitis Suppurativa Products Market Share (%), US, 2018

For more information about this report visit https://www.researchandmarkets.com/r/zhwf0t

View source version on businesswire.com: https://www.businesswire.com/news/home/20190719005321/en/

Source link

Health Care Sector Update for 07/19/2019: GLPG,MTP,IFRX

Top Health Care Stocks

JNJ -0.56%

PFE +0.15%

ABT +0.40%

MRK -1.04%

AMGN +0.24%

Health care stocks were lower this afternoon, with the NYSE Health Care Index sinking over 0.4% in recent trade while shares of health care companies in the S&P 500 also were down almost 0.4% as a group. The Nasdaq Biotechnology index was falling over 0.8%.

Among health care stocks moving on news:

(+) Galapagos ( GLPG ) climbed over 5% on Friday after a new regulatory filing showed Van Herk Investments BV owns more than 10% of the specialty drugmaker’s stock, with the Dutch private equity firm holding nearly 4.9 million ordinary Galapagos shares and 893,239 of its American depositary receipts. Based on Galapagos’ 54.8 million outstanding shares, Van Herk owns 10.57% of the company following its July 15 stock purchases.

In other sector news:

(+) Midatech Pharma ( MTP ) still was 48.5% higher on Friday, drifting off a 109% early-morning peak, after announcing positive results from a first-in-human clinical trial of its MTX102 immuno-tolerising vaccine product candidate in patients with diabetes. No serious adverse events were reported in the study.

(-) InflaRx NV ( IFRX ) was 5% lower after the specialty drugmaker reported additional data from its ongoing phase IIb study of its IFX-1 product candidate, saying it show robust anti-inflammatory activity in the high-dose group of patients with moderate to severe hidradenitis suppurativa.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

Source link

Analysts See $-0.55 EPS for InflaRx N.V. (IFRX); Anchor Capital Advisors Has Lowered By $1.58 Million Its Boston Scientific (BSX) Holding

Boston Scientific Corporation (NYSE:BSX) Logo

Anchor Capital Advisors Llc decreased Boston Scientific Corp (BSX) stake by 3.46% reported in 2019Q1 SEC filing. Anchor Capital Advisors Llc sold 41,534 shares as Boston Scientific Corp (BSX)’s stock declined 6.39%. The Anchor Capital Advisors Llc holds 1.16M shares with $44.48 million value, down from 1.20M last quarter. Boston Scientific Corp now has $59.36 billion valuation. The stock increased 1.05% or $0.44 during the last trading session, reaching $42.69. About 3.94M shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 24.15% since July 18, 2018 and is uptrending. It has outperformed by 19.72% the S&P500. Some Historical BSX News: 25/04/2018 – Boston Scientific Sees 2Q EPS 21c-EPS 23c; 25/04/2018 – Boston Scientific Sees FY EPS 90c-EPS 94c; 21/03/2018 – Boston Scientific: NxThera Acquisition Expands Portfolio With Minimally Invasive Therapy for Benign Prostatic Hyperplasia; 25/04/2018 – BSX SEES FY ADJ EPS $1.37 TO $1.41, SAW $1.35 TO $1.39; 26/03/2018 – Boston Scientific Presenting at Conference Tomorrow; 23/03/2018 – Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid; 16/04/2018 – BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH; 16/04/2018 – BOSTON SCIENTIFIC CORP – ACQUISITION IS EXPECTED TO BE ACCRETIVE ON AN ADJUSTED BASIS AFTER 2018 AND 2019; 19/03/2018 – FDA: Boston Scientific Corporation- SpyScope DS Access and Delivery diagnostic biliary catheter, M00546600; 21/03/2018 – Boston Scientific Enters Definitive Agreement to Acquire Privately-Held NxThera for $306M Upfront Cash Paymen

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.55 EPS on August, 8.They anticipate $0.43 EPS change or 358.33% from last quarter’s $-0.12 EPS. After having $-0.43 EPS previously, InflaRx N.V.’s analysts see 27.91% EPS growth. The stock increased 1.85% or $0.0566 during the last trading session, reaching $3.1166. About 562,977 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since July 18, 2018 and is uptrending. It has outperformed by 16.11% the S&P500. Some Historical IFRX News: 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Finance.Yahoo.com which released: “Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) – Yahoo Finance” on June 29, 2019, also Nasdaq.com with their article: “InflaRx Enters Oversold Territory – Nasdaq” published on July 18, 2019, Benzinga.com published: “28 Stocks Moving In Friday’s Pre-Market Session – Benzinga” on July 12, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Full Year 2018 Financial & Operating Results – GlobeNewswire” published on March 28, 2019 as well as Finance.Yahoo.com‘s news article titled: “Did Hedge Funds Drop The Ball On InflaRx N.V. (IFRX)? – Yahoo Finance” with publication date: May 03, 2019.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $80.92 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

More notable recent Boston Scientific Corporation (NYSE:BSX) news were published by: Finance.Yahoo.com which released: “Here’s Why I Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today – Yahoo Finance” on July 08, 2019, also Finance.Yahoo.com with their article: “Are Boston Scientific Corporation’s (NYSE:BSX) Interest Costs Too High? – Yahoo Finance” published on June 20, 2019, 247Wallst.com published: “5 Medtech Companies May Be Winning at Johnson & Johnson’s Expense – 24/7 Wall St.” on July 18, 2019. More interesting news about Boston Scientific Corporation (NYSE:BSX) were released by: Finance.Yahoo.com and their article: “Stocks – S&P Closes Above 3,000 as Wall Street’s Rally on Rate Hopes Continues – Yahoo Finance” published on July 12, 2019 as well as Prnewswire.com‘s news article titled: “Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group – PRNewswire” with publication date: June 28, 2019.

Investors sentiment increased to 1.38 in 2019 Q1. Its up 0.24, from 1.14 in 2018Q4. It improved, as 36 investors sold BSX shares while 185 reduced holdings. 92 funds opened positions while 213 raised stakes. 1.21 billion shares or 1.61% less from 1.23 billion shares in 2018Q4 were reported. Invesco Limited reported 8.61M shares. Veritable LP reported 0.02% in Boston Scientific Corporation (NYSE:BSX). Caisse De Depot Et Placement Du Quebec has invested 0.02% in Boston Scientific Corporation (NYSE:BSX). Lazard Asset holds 0.08% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 1.20M shares. Scotia has 11,807 shares for 0.01% of their portfolio. Keybank Association Oh holds 13,948 shares or 0% of its portfolio. Royal Commercial Bank Of Canada holds 2.39 million shares. Gotham Asset Management Ltd Com reported 0.01% in Boston Scientific Corporation (NYSE:BSX). Grimes Com Inc reported 10,984 shares. Alliancebernstein Limited Partnership holds 7.09 million shares or 0.18% of its portfolio. Focused Wealth stated it has 3,950 shares or 0.05% of all its holdings. Crestwood Gp Limited Liability Company has 8,045 shares. Tekla Capital Mngmt Ltd Limited Liability Company owns 473,619 shares. Nomura invested in 0.05% or 320,558 shares. National Asset Mngmt has 7,433 shares.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on July, 24. They expect $0.38 earnings per share, down 7.32% or $0.03 from last year’s $0.41 per share. BSX’s profit will be $528.39 million for 28.09 P/E if the $0.38 EPS becomes a reality. After $0.35 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 8.57% EPS growth.

Among 3 analysts covering Boston Scientific Corp (NYSE:BSX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Boston Scientific Corp had 7 analyst reports since March 18, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Monday, March 18 by Bank of America. On Tuesday, June 18 the stock rating was maintained by Wells Fargo with “Outperform”. On Wednesday, April 17 the stock rating was maintained by Canaccord Genuity with “Buy”. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, June 27.

Since February 1, 2019, it had 0 insider purchases, and 2 insider sales for $1.96 million activity. Shares for $190,750 were sold by Pierce David A. $1.77 million worth of Boston Scientific Corporation (NYSE:BSX) was sold by Fitzgerald Joseph Michael.

Boston Scientific Corporation (NYSE:BSX) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link